Form 4: Intuitive Surgical Executive Robert DeSantis Exercises and Sells Stock Options Under 10b5-1 Plan
SEC Form 4
Robert DeSantis, EVP & Chief Strategy & Corp Op at Intuitive Surgical, executed multiple transactions involving stock options and common stock sales under a pre-arranged 10b5-1 trading plan.
Summary
- Robert DeSantis, an executive at Intuitive Surgical, engaged in multiple transactions involving the exercise of non-qualified stock options and the subsequent sale of common stock.
- These transactions were executed on July 26, 2024, and July 29, 2024.
- The exercises and sales were conducted under a pre-arranged trading plan that complies with SEC Rule 10b5-1, which is set to expire on December 9, 2024.
- The prices at which the options were exercised varied, ranging from $208.9 to $347.4167.
- The sales of the resulting common stock were executed at prices of $438.6 and $446.6.
- Following these transactions, DeSantis directly owns 5,506 shares of Intuitive Surgical common stock.
- He also holds various non-qualified stock options with different exercise prices and expiration dates.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The transactions are part of a pre-planned trading strategy and do not necessarily reflect a change in the executive's outlook on the company.
Positives
- The transactions were conducted under a pre-arranged 10b5-1 trading plan, indicating compliance with SEC regulations and potentially mitigating concerns about insider trading.
Risks
- Executive stock sales can sometimes be perceived negatively by investors, although the use of a 10b5-1 plan mitigates this concern.
Future Outlook
The executive will continue to execute transactions under the 10b5-1 trading plan until its expiration on December 9, 2024.
Industry Context
Executive stock transactions are common in publicly traded companies and are closely monitored by investors for insights into management's perspective on the company's performance and future prospects. The use of a 10b5-1 plan is a standard practice to avoid insider trading concerns.
Comparison to Industry Standards
- Executive compensation practices, including stock options, are common across the medical device industry.
- Companies like Medtronic, Stryker, and Johnson & Johnson also utilize stock options as part of their executive compensation packages.
- The vesting schedules and exercise prices of these options are generally aligned with industry norms to incentivize long-term performance and retention.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the potential dilution from the exercise of stock options.
- However, the use of a 10b5-1 plan mitigates concerns about insider trading and ensures transparency.
Key Dates
| Date | Description |
|---|---|
| 02/10/2023 | Date relevant to the vesting schedule of some stock options. |
| 08/10/2023 | Date relevant to the vesting schedule of some stock options. |
| 07/26/2024 | Date of multiple stock option exercises and sales. |
| 07/29/2024 | Date of multiple stock option exercises and sales. |
| 07/30/2024 | Date of the report. |
| 08/28/2029 | Expiration date of some non-qualified stock options. |
| 02/27/2030 | Expiration date of some non-qualified stock options. |
| 08/09/2030 | Expiration date of some non-qualified stock options. |
| 02/26/2031 | Expiration date of some non-qualified stock options. |
| 08/26/2031 | Expiration date of some non-qualified stock options. |
| 12/09/2024 | Expiration date of the 10b5-1 trading plan. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.